Eli Lilly and Co. has been counting on torrid growth in China to help offset losses from patent expirations in other markets, but now slower growth in the Chinese economy and bribery allegations against Lilly and two other drugmakers have hampered Lilly’s growth there.
Obamacare’s exchanges are requiring working Americans to grasp minute details of their employers’ health plans in order to avoid a nasty surprise from the IRS.
Indiana companies are planning different methods to adapt to the health care landscape next year.
It’s long been known that Obamacare would make health benefits more expensive for most employers. Now, it’s finally becoming clearer by how much: about 9 percent, on average, according to a series of actuarial studies.
The Indiana-based system that operates three hospitals in the Indianapolis area said it is trying to cut its expenses by as much as $500 million, or 20 percent.
Excluding a one-time payment from a year ago, Eli Lilly and Co.’s third-quarter profit easily beat Wall Street’s expectations.
The giant health insurer raised its full-year profit forecast 40 cents per share, emboldened by stabilized customer rolls and slowing medical claims.
Only four health insurers are offering policies in the Obamacare exchange in Indiana, whereas 17 have withdrawn from the market since 2010.
Indiana life sciences companies trying to raise venture capital continue to do so with a national wind in their faces, according to the third-quarter venture capital data.
The premiums offered by health insurers participating in the Obamacare exchanges put Indiana among the 10 most-expensive states in the country, according to data released last month by the U.S. Department of Health and Human Services.
Rather than railing incessantly against Obamacare, Republicans would do themselves and the country a favor if they finally agreed on a common alternative for fixing the health care system.
Investors on Friday dumped shares of West Lafayette-based Endocyte Inc. after an independent analysis said an experimental lung cancer drug is unlikely to be declared superior to existing chemotherapy. But two analysts say, to the contrary, the analysis shows the prospects for Endocyte’s drug are as good as ever.
More than half of the $2.5 trillion consumers spend annually on health care in the United States flows to hospitals and doctors, with drug companies and health insurers trailing well behind.
In a new round of predictions this month, Wall Street analysts indicated they expect Eli Lilly and Co.’s revenue to fall next year and to remain below 2013 levels until 2020.
With payment reform and new technology, it’s plausible that health care will shift from being a bricks and mortar business to an information business–bringing us higher quality and lower costs. That’s exciting.
Indianapolis-based Novia CareClinics LLC was a pioneer in operating primary care clinics for employers. In 2012, Novia had 175 employees and more than $15 million in revenue.
Three former employees of Eli Lilly and Co. allegedly transferred trade secrets that Lilly values at more than $55 million to a competing Chinese drug company, according to an indictment unsealed Tuesday in federal court.
In a series of presentations, Lilly executives stretched themselves in four directions at once to convince investors and stock analysts that the company will bend but not break next year, and then snap back stronger than ever in 2015.
Eli Lilly and Co. said Thursday that meeting its sale target will be a challenge. It plans to repurchase $5 billion in shares and introduce new diabetes drugs to help navigate through patent losses. Another immediate hurdle: Obamacare.
Before this year’s cuts, Indiana hospitals had added 12,000 jobs over the past six years, even as private employers across Indiana, collectively, added no net new workers.
